The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 6 of the 15 sources its claims cite were checked for support.
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency
Open accessAbstract
The magnitude of weight reduction in the SURMOUNT-1 trial of the dual GLP-1 and GIP receptor agonist tirzepatide suggests that this treatment may be particularly effective in addressing the treatment needs of people with severe obesity (body mass index >40 kg m−2), some of whom may carry rare penetrant genetic variants. Here we investigated the clinical response of men and women in the SURMOUNT-1 trial who carried pathogenic mutations in the melanocortin 4 receptor (MC4R) gene, the most common genetic cause of obesity. We found that 32 of 2,291 people (1.4%) for whom data were available carried pathogenic MC4R mutations. At baseline, MC4R mutation carriers exhibited a higher body mass index compared with noncarriers (40 kg m−2 versus 38 kg m−2; P = 0.036). In the treatment arm, the weight loss trajectory over 72 weeks was comparable in both groups: 18.3% weight reduction in MC4R mutation carriers versus 19.9% in noncarriers. We conclude that tirzepatide is an effective treatment for the most common genetic subtype of obesity, MC4R deficiency.
Overview
CoChat Summary
TL;DR
In a genetic substudy of SURMOUNT-1, people with obesity carrying pathogenic MC4R mutations lost weight on tirzepatide similarly to noncarriers over 72 weeks. The authors conclude tirzepatide is effective for MC4R deficiency, the most common genetic subtype of obesity.
Key findings
- Among 2,291 genotyped SURMOUNT-1 participants, 32 (1.4%) carried pathogenic MC4R mutations; carriers had higher baseline BMI than noncarriers (40 kg m−2 versus 38 kg m−2; P = 0.036) and greater waist circumference (120.44 cm versus 114.02 cm; P = 0.012).
- At 72 weeks, weight reduction was comparable in MC4R mutation carriers versus noncarriers: 18.3% versus 19.9%.
- The genotype–treatment interaction was not significant (beta coefficient −0.88, SEM 3.2; unadjusted two-sided P = 0.79), and there was no differential impact of treatment versus placebo on metabolic parameters in carriers versus noncarriers.
- People carrying gain-of-function MC4R variants V103I or I251L (n = 88) were excluded from all analyses.
Methods
- Post hoc genetic analysis of the randomized controlled SURMOUNT-1 trial of tirzepatide versus placebo in adults with BMI ≥30 kg m−2, or ≥27 kg m−2 with at least one weight-related comorbidity.
- DNA was available for 2,291 participants (90% of those randomized); samples were genotyped with a customized Affymetrix Axiom Biobank array, yielding 646,504 variants and 2,291 samples after quality control.
- Weight-loss percentage change at week 72 was analyzed using REGENIE gene-level collapsed burden testing for 14 MC4R loss-of-function mutations with treatment interaction, and mixed-model repeated-measures least-squares means were used to estimate weight trajectories.
Limitations
- The paper notes that all placebo-treated MC4R mutation carriers were female, which it attributes probably to chance given the rarity of MC4R deficiency and the trial’s female predominance.
- The paper states that ongoing studies of safety and efficacy of chronic obesity medications are important, and that trials of tirzepatide and other obesity medications in children and adolescents with obesity, including MC4R deficiency, are needed.
- Evident from the text: the MC4R carrier group was small (n = 32), limiting precision for subgroup comparisons, and the analysis is a genetic substudy of a trial not designed specifically to test tirzepatide efficacy in MC4R deficiency.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
4 Valid · 2 Not valid · 4 Not checked · 18 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“clinical trials of a MC4R agonist have not demonstrated efficacy in this patient group17.”
§ Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency > Main
What the sources say
- Disputedcites [17] Collet, T.-H. et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol. Metab. 6, 1321–1329 (2017). sourceExperimental — accuracy not yet measured
The Discussion states that setmelanotide can lead to weight loss in people with MC4R deficiency, contrary to the claim that trials have not demonstrated efficacy in this group. The Results qualify that finding: the approximately 0.6 kg/week difference from placebo did not reach statistical significance (p = 0.09), and the paper calls for further studies to establish clinically meaningful weight loss. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Two studies have shown that intense dietary and physical activity interventions11,16 are less effective in children with MC4R deficiency, and weight reduction is harder to maintain in this group.”
§ Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency > Main
What the sources say
- Disputedcites [11] Trier, C. et al. Obesity treatment effect in Danish children and adolescents carrying melanocortin-4 receptor mutations. Int J. Obes. 45, 66–76 (2021). sourceExperimental — accuracy not yet measured
The Discussion says the paper's own lower-intensity program produced a poorer BMI response in MC4R mutation carriers, but explicitly contrasts that result with more intensive studies in which carriers and noncarriers lost similar amounts of weight. The Introduction does say carriers may have difficulty maintaining weight loss. Thus the maintenance point has support, but the claim that intensive interventions are less effective is contrary to the paper's account. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [16] Reinehr, T. et al. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene. Obesity 17, 382–389 (2009). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and weight reduction is harder to maintain in this group.”
§ Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency > Main
What the sources say
- Partly supportedcites [11] Trier, C. et al. Obesity treatment effect in Danish children and adolescents carrying melanocortin-4 receptor mutations. Int J. Obes. 45, 66–76 (2021). sourceExperimental — accuracy not yet measured
The Discussion reports that only some children carrying MC4R mutations in a Spanish study maintained their BMI-SDS reduction after one year. It does not give a comparable maintenance result for noncarriers. This paper’s own results show a poorer response during treatment, not greater difficulty maintaining an achieved reduction. (LLM, conf=0.84)
- Not checked yetcites [16] Reinehr, T. et al. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene. Obesity 17, 382–389 (2009). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“there is evidence from a small clinical study with liraglutide20 that they may be effective in people with MC4R deficiency.”
§ Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency > Main
What the sources say
- Supportedcites [20] Iepsen, E. W. et al. Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist. Cell Metab. 28, 23–32 (2018). source
The ‘Liraglutide as Treatment for MC4R Causal Obesity’ section reports clinically relevant weight loss after liraglutide treatment in participants with pathogenic MC4R mutations. The ‘Limitations of Study’ section identifies this as a small study of 14 mutation carriers and notes that larger studies are warranted. The participants were heterozygous carriers, so the evidence does not establish efficacy in homozygous deficiency. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“GLP-1 receptor agonists predominantly target non-MC4R-dependent neural pathways in mice19”
§ Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency > Main
What the sources say
- Partly supportedcites [19] Clemmensen, C. et al. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. EMBO Mol. Med. 7, 288–298 (2015). sourceExperimental — accuracy not yet measured
The Results report anorectic effects of liraglutide and the MC4R agonist RM-493 individually, consistent with distinct contributions. But the Discussion says that how MC4R- and GLP-1R-positive neurons interact remains to be established; it does not show that GLP-1R agonists predominantly act through MC4R-independent neural pathways in mice. Page numbers are unavailable in our copy. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
15 more claims
Create a free account to see all 28 claims and to verify the 9 references still open.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency > Main
“People carrying either of the two prevalent gain-of-function MC4R variants (V103I and I251L; n = 88), associated with lower BMI in cohort studies21, were excluded from all analyses.”
§ Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency > Main
“We compared the weight loss trajectory at 72 weeks in the 32 MC4R mutation carriers and 2,259 noncarriers.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Female sex, no. (%) | 20 (62%) | 154 (68%) | |”
§ Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency > Main
Reported 68 · recomputed 6.817176
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“%) in people with obesity, with and without type 2 diabetes 2,3 .”
Self-citationTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“%) in people with obesity, with and without type 2 diabetes 2,3 .”
Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene
Farooqi, I. S., Keogh, J. M., Yeo, G. S. H., Lank, E. J., Cheetham, T., & O'Rahilly, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022050 · Cited by 1,778
Self-citationComputationally efficient whole-genome regression for quantitative and binary traits
Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J. A., Ziyatdinov, A., Benner, C., O’Dushlaine, C., Barber, M., Boutkov, B., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00870-7 · Cited by 1,502
Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood
Khera, A. V., Chaffin, M., Wade, K. H., Zahid, S., Brancale, J., Xia, R., Distefano, M., Senol-Cosar, O., Haas, M. E., Bick, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.028 · Cited by 789
Self-citationModulation of Blood Pressure by Central Melanocortinergic Pathways
Greenfield, J. R., Miller, J. W., Keogh, J. M., Henning, E., Satterwhite, J. H., Cameron, G. S., Astruc, B., Mayer, J. P., Brage, S., See, T. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803085 · Cited by 477 · cited 1×
“Adults with MC4R deficiency often have severe obesity but with a lower prevalence of hypertension and reduced systolic and diastolic blood pressure associated with impaired sympathetic nervous system tone 14,15 .”
Self-citationTurcot, V., Lu, Y., Highland, H. M., Schurmann, C., Justice, A. E., Fine, R. S., Bradfield, J. P., Esko, T., Giri, A., Graff, M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0011-x · Cited by 409
The Hunger Genes: Pathways to Obesity
van der Klaauw, A. A., & Farooqi, I. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.008 · Cited by 393
Self-citationEvaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
Collet, T.-H., Dubern, B., Mokrosinski, J., Connors, H., Keogh, J. M., Mendes de Oliveira, E., Henning, E., Poitou-Bernert, C., Oppert, J.-M., Tounian, P., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.015 · Cited by 302
Self-citationHuman gain-of-function MC4R variants show signaling bias and protect against obesity
Lotta, L. A., Mokrosiński, J., Mendes de Oliveira, E., Li, C., Sharp, S. J., Luan, J., Brouwers, B., Ayinampudi, V., Bowker, N., Kerrison, N., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.044 · Cited by 284
Self-citation
Cited by
Zorn, S., Bounds, R., Williamson, A., Lawler, K., Hanßen, R., Keogh, J. M., Henning, E., Smith, M., Fielding, B. A., Umpleby, A. M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03976-1 · Cited by 28
Self-citationResistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure
Nicze, M., Borówka, M., Dec, A., Bułdak, Ł., Bołdys, A., & Okopień, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062539 · Cited by 7
Monogenic obesity due to MC4R deficiency: lessons from a multigenerational case
Giannopoulou, E. Z., Zorn, S., Schirmer, M., Brandt-Heunemann, S., von Schnurbein, J., Nestoris, C., Moawia, A., Siebert, R., Denzer, C., & Wabitsch, M. (2026) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-025-00214-z · Cited by 6
Cho, Y. K., & Jung, C. H. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0744 · Cited by 5
A new era in childhood obesity
Martos‐Moreno, G. Á., Guijo, B., Tena‐Sempere, M., Chowen, J. A., & Argente, J. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.03.006 · Cited by 5
Metadata
- Authors
- Bhatnagar, P., Ahmad, N. N., Li, X., Coghlan, M., Kaplan, L. M., & Farooqi, I. S.
- Affiliations
- Eli Lilly (United States) (US)
- Dartmouth College (US)
- Wellcome/MRC Institute of Metabolic Science (GB)
- Corresponding author
- Farooqi, I. Sadaf
- Venue
- Nature Medicine
- Published
- 2025-08-26
- Volume
- 31
- Issue
- 10
- Pages
- 3294-3296
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC12532586
- OpenAlex
- W4413706535
- Semantic Scholar
- 298da475a630a5d3f3169bbaa114319be8daf609
- Cited by
- 20
- References
- 24
- Citations by year
- 2026: 18 · 2025: 2
- FWCI
- 11.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Eli Lilly and Company
- Wellcome Trust (207462/Z/17/Z)
- Government of the United Kingdom
- National Institute for Health and Care Research
- Department of Health and Social Care
- Fondation Botnar
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- tirzepatide, melanocortin-4 receptor, genetic obesity, morbid obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, pathogenic variants, body mass index
- MeSH terms
- Tirzepatide, Adult, Female, Humans, Male, Middle Aged, Mutation, Obesity, Receptors, Gastrointestinal Hormone, Weight Loss, Body Mass Index, Receptor, Melanocortin, Type 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency. https://app.cochat.ai/papers/10.1038/s41591-025-03913-2
- The paper
- Bhatnagar, P., Ahmad, N. N., Li, X., Coghlan, M., Kaplan, L. M., & Farooqi, I. S. (2025). Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency. Nature Medicine. https://doi.org/10.1038/s41591-025-03913-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.